Table 3.
Clinical Trials Assessing the Safety and Efficacy of Combining KRAS Exon 2 P. G12C Inhibitors with Other Cancer Therapies
| Combination Target | Combination Options | NCT Number | Phase |
|---|---|---|---|
| PD1/PD-L1 | Sotorasib + Pembrolizumab |
NCT04185883 NCT03600883 |
I/II |
| Adagrasib + Pembrolizumab |
NCT04613596 NCT03785249 |
II | |
| Sotorasib + AMG404 | NCT04185883 | I/II | |
| GDC-6036 + Atezolizumab | NCT04449874 | I | |
| LY3537982 + Sintilimab | NCT04956640 | I/II | |
| JDQ443 + Spartalizumab ±TNO155 | NCT04699188 | Ib/II | |
| SHP2 inhibitors | Sotorasib + RMC4630 |
NCT04185883 NCT05054725 |
II |
| Sotorasib + TNO155 | NCT04449874 | I | |
| Adagrasib + TNO155 | NCT04330664 | I/II | |
| GDC-6036 + GDC-1971 | NCT04185883 | I/II | |
| JDQ443 + TNO155 ±Spartalizumab | NCT04699188 | Ib/II | |
| SOS1 inhibitors | Adagrasib + BI1701963 | NCT04975256 | I/Ib |
| EGFR and pan ERBB inhibitors | Adagrasib + Afatinib | NCT03785249 | I/II |
| Sotorasib + Afatinib | NCT04185883 | I/II | |
| Sotorasib + MVASI | NCT05180422 | I/II | |
| JDQ443 + Cetuximab | NCT05358249 | Ib/II | |
| LY3537982 + Cetuximab | NCT04956640 | I/II | |
| LY3537982 + erlotinib | NCT04956640 | I/II | |
| GDC-6036 + Cetuximab | NCT04449874 | I | |
| GDC-6036 + Erlotinib | NCT04449874 | I | |
| MEK inhibitor | Sotorasib + Trametinib | NCT04185883 | I/II |
| Sotorasib + Avutometinib | NCT05074810 | I/II | |
| JDQ443 + Trametinib | NCT05358249 | Ib/II | |
| ERK inhibitors | LY3537982 + Temuterkib | NCT04956640 | I/II |
| mTOR inhibitor | Sotorasib + Everolimus | NCT04185883 | I/II |
| CDK4/6 inhibitors | LY3537982 + Abemaciclib | NCT04956640 | I/II |
| Sotorasib + Palbociclib | NCT04185883 | I/II | |
| Adagrasib + Palbociclib | NCT05178888 | I | |
| JDQ443 + Ribociclib | NCT05358249 | Ib/II |
Abbreviations: PD-1/PD-L1, programmed cell death protein 1/programmed cell death protein 1 ligand; SHP2, src homology region 2 domain-containing phosphatase-2; SOS1, son of sevenless homolog 1; EGFR, epidermal growth factor receptor; ERBB, The family of ERBB or epidermal growth factor (EGF) receptors includes four members: EGFR/ERBB1, ERBB2, ERBB3 and ERBB4. EGFR and ERBB2; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase; ERK, extracellular regulated protein kinases; mTOR, mammalian target of rapamycin; CDK 4/6, cyclin-dependent kinase 4/6.